Robert Martin House, JR
Physician at Hinsdale Pl, Denver, CO

License number
Colorado 20188
Issued Date
Jul 13, 1976
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
7040 E Hinsdale Pl, Denver, CO 80112

Personal information

See more information about Robert Martin House at radaris.com
Name
Address
Phone
Robert House
3782 S Genoa Cir UNIT B, Aurora, CO 80013
Robert J House
2435 Gilpin St, Denver, CO 80205
(303) 837-9918
Robert J House
3782 Genoa Cir, Aurora, CO 80013

Professional information

Robert M House Photo 1

Robert M House, Denver CO

Specialties:
Psychiatrist
Address:
777 Bannock St, Denver, CO 80204
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)


Robert House Photo 2

Dr. Robert House, Denver CO - MD (Doctor of Medicine)

Specialties:
Neuropsychiatry (Psychiatry)
Address:
777 Bannock St, Denver 80204
(303) 436-6000 (Phone), (303) 436-5184 (Fax)
12605 E 16Th Ave, Aurora 80045
(720) 848-0000 (Phone)
Certifications:
Psychiatry, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
777 Bannock St, Denver 80204
12605 E 16Th Ave, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Education:
Medical School
University of Nebraska / College of Medicine
Graduated: 1975


Robert House Photo 3

Robert House, Denver CO

Work:
Psychiatry Svc. 116
667 Bannock St, Denver, CO 80204


Robert House Photo 4

Schizophrenia Treatment Response Biomarkers

US Patent:
2012020, Aug 16, 2012
Filed:
Oct 1, 2010
Appl. No.:
13/499672
Inventors:
Judith Morse Gault - Aurora CO, US
Ann Olincy - Morrison CO, US
Robert House - Centennial CO, US
Bifeng Gao - Highlands Ranch CO, US
Assignee:
THE REGENTSN OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE - Denver CO
International Classification:
C40B 30/04, C12Q 1/68, C40B 40/06
US Classification:
506 9, 506 16, 435 612
Abstract:
The present invention provides biomarker of antipsychotic treatment response in patients with schizophrenia and other disorders involving DRD2 and methods for using the same.